Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer

June 19, 2013

Highly sensitive and accurate test detects cancer-related microRNA in blood of patients even before the development of colorectal cancer DALLAS, June 19, 2013 /PRNewswire-USNewswire/ – A new blood test developed in the Gastrointestinal Cancer Research Lab at Baylor Research Institute is showing very promising results for finding cancer-related microRNA in the blood before a tumor develops […]

Read the full article →

Release of miRBase 20 approaching

June 17, 2013

It has been almost a year since the last miRBase update and according to Sam from miRBase we should see the release of miRBase 20  within this week: “As you might expect, the extended period since the last release means many new entries — over 3000 new stem-loop sequences, and over 5000 new mature sequences. […]

Read the full article →

EGEN, Inc. Advances a Systemically Delivered anti-miR-145 for the Treatment of Pulmonary Arterial Hypertension (PAH)

June 5, 2013

HUNTSVILLE, Ala., June 5, 2013 /PRNewswire/ — EGEN, Inc., a clinical stage biopharmaceutical  company, announced today that  EGEN’s proprietary lung targeting Staramine-mPEG nanoparticle delivery system has been used to administer an inhibitor of microRNA-145 (anti-miRNA-145) in a rat model of severe occlusive PAH.  Treatment was shown to significantly reverse the pulmonary hypertension associated with the advanced […]

Read the full article →

miRagen Therapeutics: First Milestone in Strategic Alliance with Servier

May 23, 2013

Servier selects third cardiovascular target triggering the first milestone under the collaboration SURESNES, France, and BOULDER, Colo., May 23, 2013 – Servier, a privately-run French research-based pharmaceutical company and a major player in Europe and emerging markets having expertise in the development of treatments for cardiovascular diseases, and miRagen Therapeutics, Inc., a biopharmaceutical company developing […]

Read the full article →

Mirna Therapeutics is First to Advance MicroRNA into the Clinic for Cancer

May 15, 2013

Phase 1 Clinical Trial of Anticancer Drug MRX34 Underway AUSTIN, TX (May 13, 2013)– Mirna Therapeutics, Inc., a biotechnology company pioneering microRNA (miRNA) replacement therapies for cancer, announced today that it has initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial for cancer. The Phase 1 […]

Read the full article →

Regulus Provides Update on ‘Road to the Clinic’ Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights

May 14, 2013

- Nominated RG-101 in HCV as First microRNA Candidate for Clinical Development- – Maintained Strong Financial Position with Over $90 million in Cash- LA JOLLA, Calif., May 14, 2013 /PRNewswire/ – Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today provided an update on its microRNA […]

Read the full article →

Call for Papers

April 16, 2013

Call for papers for an open special issue on small/microRNAs: Small RNAs: Revolutionizing the Genomics Landscape The editors invite researchers to contribute original research articles as well as review articles focused on the use, development, or the application of genomics tools for investigating the role of small RNAs at the whole-genome level. The editors will […]

Read the full article →

Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 AACR Anual Meeting

April 8, 2013

NEW YORK, April 8, 2013 /PRNewswire/ – Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C.  The abstract is titled “Exosome profiling of mRNAs and miRNAs in serum samples from GBM (glioblastoma […]

Read the full article →

Antiviral Drug Miravirsen: Final Phase 2a results show dose-dependent, prolonged antiviral activity in Hepatitis C patients

March 27, 2013

Research Published in the New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S’ Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials HOERSHOLM, Denmark and SAN DIEGO, March 27, 2013 /PRNewswire/ — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted […]

Read the full article →

Invitation to contribute with a book chapter on methods related to microRNAs and long non-coding RNAs for a book on “Structural and Functional RNA Mapping”

March 25, 2013

Dr. Lucrecia Alvarez is currently editing one of the Springer Book Series on Methods in Molecular Biology entitled “Structural and Functional RNA Mapping” and is looking for contributions: “All I am asking the authors to do is to present their routinely laboratory protocols in a define format and, therefore, there is not too much work […]

Read the full article →